These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 37084609)
1. Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis. Wang Y; Xu H; Han Y; Wu Y; Sa Q; Wang J ESMO Open; 2023 Jun; 8(3):101216. PubMed ID: 37084609 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120 [TBL] [Abstract][Full Text] [Related]
3. Second-line Endocrine Therapy of Hormone Receptor-positive/HER2- negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis. Wang T; Shen G; Li J; Huo X; Wang M; Liu Z; Zhao F; Ren D; Zhao J Curr Cancer Drug Targets; 2023; 23(9):718-730. PubMed ID: 37026492 [TBL] [Abstract][Full Text] [Related]
4. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287 [TBL] [Abstract][Full Text] [Related]
5. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ J Clin Oncol; 2018 Mar; 36(8):741-748. PubMed ID: 29244528 [TBL] [Abstract][Full Text] [Related]
6. HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials. Li X; Wu S; Zhang L; Zhu J; Xu B Ann Transl Med; 2020 Dec; 8(24):1634. PubMed ID: 33490146 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials. Wang J; Yu Y; Lin Q; Zhang J; Song C J Cancer Res Clin Oncol; 2024 Jan; 150(1):21. PubMed ID: 38244085 [TBL] [Abstract][Full Text] [Related]
8. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037 [TBL] [Abstract][Full Text] [Related]
9. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598 [TBL] [Abstract][Full Text] [Related]
11. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963 [TBL] [Abstract][Full Text] [Related]
12. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis. Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880 [TBL] [Abstract][Full Text] [Related]
13. Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis. Cai YW; Shao ZM; Yu KD Front Immunol; 2022; 13():919369. PubMed ID: 35844533 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. Han Y; Wang J; Wang Z; Xu B Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638 [TBL] [Abstract][Full Text] [Related]
15. A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer. Xie BJ; Zhu LN; Ma C; Li JB; Dong L; Zhu ZN; Ding T; Gu XS Breast Cancer; 2020 Mar; 27(2):186-196. PubMed ID: 31529262 [TBL] [Abstract][Full Text] [Related]
16. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis. Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326 [TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-containing regimens for metastatic breast cancer. Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of first-line regimens for advanced HER2-positive breast cancer: A Bayesian network meta-analysis. Li L; Wu Y; Lan B; Ma F Cancer Innov; 2024 Aug; 3(4):e126. PubMed ID: 38948247 [TBL] [Abstract][Full Text] [Related]
19. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis. Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129 [TBL] [Abstract][Full Text] [Related]
20. Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. Brandão M; Maurer C; Ziegelmann PK; Pondé NF; Ferreira A; Martel S; Piccart M; de Azambuja E; Debiasi M; Lambertini M ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32847835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]